Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INO
  • CUSIP:
Key Metrics:
  • Previous Close: $6.60
  • 50 Day Moving Average: $6.71
  • 200 Day Moving Average: $7.79
  • 52-Week Range: $5.85 - $11.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.06
  • P/E Growth: 0.00
  • Market Cap: $488.80M
  • Outstanding Shares: 74,060,000
  • Beta: 2.84
Profitability:
  • Net Margins: -199.99%
  • Return on Equity: -39.93%
  • Return on Assets: -31.81%
Debt:
  • Current Ratio: 3.39%
  • Quick Ratio: 3.39%
Additional Links:
Companies Related to Inovio Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $14.00 (112.12% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
DateFirmActionRatingPrice TargetDetails
12/23/2016Stifel NicolausReiterated RatingBuy$11.00View Rating Details
12/23/2016HC WainwrightReiterated RatingBuy$13.00View Rating Details
11/7/2016AegisInitiated CoverageBuy$12.00View Rating Details
10/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$31.00 -> $13.00View Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00View Rating Details
8/18/2016Maxim GroupReiterated RatingHoldView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.19)($0.18)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 28.72%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
DateHeadline
capitalcube.com logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : February 22, 2017 (NASDAQ:INO)
www.capitalcube.com - February 22 at 12:37 PM
News IconInovio Pharmaceuticals, Inc. (NASDAQ:INO) Daily Sentiment Score At 0.439 - Stock Observer (NASDAQ:INO)
www.thestockobserver.com - February 18 at 10:58 AM
fool.com logoBetter Buy: Novavax, Inc. vs. Inovio Pharmaceuticals - The Motley Fool - Motley Fool (NASDAQ:INO)
www.fool.com - February 18 at 10:58 AM
sbwire.com logoGlobal Zika Virus Vaccines Market Is Expected to Reach $18,697 Million by 2022; Finds New Report (NASDAQ:INO)
www.sbwire.com - February 16 at 9:48 PM
sbwire.com logoGlobal Zika Virus Vaccines Market Is Expected to Reach $18,697 Million by 2022; Finds New Report (NASDAQ:INO)
www.sbwire.com - February 16 at 9:48 PM
sbwire.com logoGlobal Zika Virus Vaccines Market Is Expected to Reach $18,697 Million by 2022; Finds New Report (NASDAQ:INO)
www.sbwire.com - February 16 at 9:48 PM
News IconStock Update on Earnings & Estimates for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Aiken Advocate (NASDAQ:INO)
aikenadvocate.com - February 15 at 9:05 PM
News IconEarnings Wrap Up & Price Target Focus on Inovio Pharmaceuticals ... - Winfield Review (NASDAQ:INO)
winfieldreview.com - February 15 at 9:05 PM
smarteranalyst.com logoStock Update (NASDAQ:INO): Inovio Pharmaceuticals Inc and ApolloBio to Collaborate on Development and ... - Smarter Analyst (NASDAQ:INO)
www.smarteranalyst.com - February 15 at 9:05 PM
News IconInovio Inks New Deal With ApolloBio Corporation (NASDAQ:INO)
www.talkmarkets.com - February 14 at 7:19 PM
4-traders.com logoInovio Pharmaceuticals Inc : Blog Coverage Inovio Inks Collaboration and License Deal with ApolloBio for Greater China (NASDAQ:INO)
www.4-traders.com - February 14 at 7:19 PM
finance.yahoo.com logoBlog Coverage Inovio Inks Collaboration and License Deal with ApolloBio for Greater China (NASDAQ:INO)
finance.yahoo.com - February 14 at 7:19 PM
4-traders.com logoS&P 500 tops $20 trillion as Wall Street eyes Trump tax cuts (NASDAQ:INO)
www.4-traders.com - February 13 at 11:58 PM
streetinsider.com logoInovio Pharma (INO) Enters Collaboration and License Agreement with ApolloBio (NASDAQ:INO)
www.streetinsider.com - February 13 at 6:57 PM
reuters.com logoBRIEF-Inovio, Apollobio to develop and commercialize hpv pre-cancer immunotherapy VGX-3100 in Greater China (NASDAQ:INO)
www.reuters.com - February 13 at 6:57 PM
investopedia.com logoInovio Inks $35M Chinese Drug License Deal (INO) (NASDAQ:INO)
www.investopedia.com - February 13 at 6:57 PM
schaeffersresearch.com logoInovio, Myriad Genetics, Zosano Pharma Stocks Moving Today (NASDAQ:INO)
www.schaeffersresearch.com - February 13 at 6:57 PM
biz.yahoo.com logoINOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:INO)
biz.yahoo.com - February 13 at 6:57 PM
finance.yahoo.com logoKey Presenters At Leerink's Healthcare Conference (NASDAQ:INO)
finance.yahoo.com - February 13 at 6:57 PM
streetinsider.com logoInovio Pharma (INO) Enters Collaboration and License Agreement ... - StreetInsider.com (NASDAQ:INO)
www.streetinsider.com - February 13 at 11:11 AM
finance.yahoo.com logoInovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China (NASDAQ:INO)
finance.yahoo.com - February 13 at 11:11 AM
finance.yahoo.com logo6:02 am Inovio Pharma enters into a collaboration and license agreement providing ApolloBio with the exclusive right to develop and commercialize VGX-3100 within Greater China; ApolloBio will invest up to $35 mln in the co (NASDAQ:INO)
finance.yahoo.com - February 13 at 11:11 AM
bizjournals.com logoPotential $70M payday: Inovio enters into licensing, equity deals with Chinese drug firm (NASDAQ:INO)
www.bizjournals.com - February 13 at 11:11 AM
investopedia.com logoInovio Inks $35M Drug Deal With Chinese Biomed (NASDAQ:INO)
www.investopedia.com - February 13 at 11:11 AM
openpr.com logoEbola And Marburg Infections Market : Technological Breakthroughs, Value Chain And Stakeholder Analysis By 2024 (NASDAQ:INO)
www.openpr.com - February 10 at 6:43 PM
News IconOncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) making strides in the $7.1 billion prostate cancer treatment space (NASDAQ:INO)
www.wallstreetpr.com - February 9 at 6:53 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Inovio Pharma, Intra-Cellular Therapies, PhaseRx, and Global Blood ... - PR Newswire (press release) (NASDAQ:INO)
www.prnewswire.com - February 8 at 11:40 PM
News IconGlobal zika virus vaccine sales available in new report (NASDAQ:INO)
www.whatech.com - February 8 at 6:39 PM
News IconGlobal Needle-Free Diabetes Management Market to Reach $16.8 Billion By 2025 by P&S Market Research (NASDAQ:INO)
www.usfinancialnewstoday.com - February 7 at 7:11 PM
proactiveinvestors.co.uk logoTrending: Is Trump trade trounced? (NASDAQ:INO)
www.proactiveinvestors.co.uk - February 6 at 6:01 PM
News IconInovio Pharmaceuticals, Inc. (NASDAQ:INO) Daily Sentiment Score ... - Stock Observer (NASDAQ:INO)
www.thestockobserver.com - February 4 at 5:58 PM
News IconZika virus UPDATE: Vaccine for WOMEN 'not expected' until 2020, WHO announce (NASDAQ:INO)
www.express.co.uk - February 2 at 11:39 PM
News IconInovio Pharmaceuticals Inc INO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:INO)
www.bioportfolio.com - February 2 at 4:43 AM
reuters.com logoZika ebbing in Latin America but vigilance needed: WHO (NASDAQ:INO)
www.reuters.com - February 1 at 11:40 PM
reuters.com logoZika ebbing in Latin America but vigilance needed - WHO (NASDAQ:INO)
in.reuters.com - February 1 at 6:40 PM
News IconStock Vacillating as Volatility Hits a High Point For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Wall Street Beacon (NASDAQ:INO)
wsbeacon.com - February 1 at 12:24 AM
fool.com logoBetter Buy: Inovio Pharmaceuticals vs. Incyte Corp. - Motley Fool (NASDAQ:INO)
www.fool.com - January 31 at 4:42 AM
News IconIs There Inherent Value in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:INO)
wsbeacon.com - January 30 at 11:41 PM
News IconPeeling Back The Layers on Inovio Pharmaceuticals, Inc. (NASDAQ:INO): Analysts & Street Weigh In - Wall Street Beacon (NASDAQ:INO)
wsbeacon.com - January 30 at 11:41 PM
News IconBetter Buy: Inovio Pharmaceuticals vs. Incyte Corp. - Fox Business (NASDAQ:INO)
www.foxbusiness.com - January 30 at 11:41 PM
News IconBetter Buy: Inovio Pharmaceuticals vs. Incyte Corp. (NASDAQ:INO)
www.foxbusiness.com - January 30 at 6:39 PM
finance.yahoo.com logoInovio Pharmaceuticals to Participate in Upcoming Investment Conferences (NASDAQ:INO)
finance.yahoo.com - January 30 at 10:42 AM
News IconChart Indicators in Focus for Inovio Pharmaceuticals Inc. (INO) - Rives Journal (NASDAQ:INO)
rivesjournal.com - January 28 at 6:04 PM
News IconInovio Pharmaceuticals, Inc. (NASDAQ:INO) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:INO)
www.thestockobserver.com - January 28 at 6:04 PM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Wall Street Beacon (NASDAQ:INO)
wsbeacon.com - January 27 at 12:38 AM
News IconEarnings in Full Force, Analysts Take Aim at Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Wall Street Beacon (NASDAQ:INO)
wsbeacon.com - January 26 at 7:37 PM
News IconQuarterly EPS Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Set At $-0.32 - Stock Observer (NASDAQ:INO)
www.thestockobserver.com - January 26 at 7:37 PM
News IconLevels in View on Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - The Tribune (NASDAQ:INO)
lakecitytribune.com - January 26 at 5:22 AM
News IconLooking Ahead for Inovio Pharmaceuticals, Inc. (NASDAQ:INO); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:INO)
aikenadvocate.com - January 26 at 5:22 AM
realistinvestor.com logoEPS Projection Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) At ... - RealistInvestor.com (NASDAQ:INO)
www.realistinvestor.com - January 26 at 5:22 AM

Social

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 1-year target prices for Inovio Pharmaceuticals' shares. Their forecasts range from $11.00 to $18.00. On average, they expect Inovio Pharmaceuticals' share price to reach $14.00 in the next twelve months.

When will Inovio Pharmaceuticals announce their earnings?

Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.44%), Allianz Asset Management AG (0.18%), Employees Retirement System of Texas (0.17%), ING Groep NV (0.12%), Russell Investments Group Ltd. (0.11%) and Metropolitan Life Insurance Co. NY (0.06%). Company insiders that own Inovio Pharmaceuticals stock include Angel Cabrera, Morton Collins, Niranjan Sardesai and Simon X Benito.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, AQR Capital Management LLC, Allianz Asset Management AG and Metropolitan Life Insurance Co. NY. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include Niranjan Sardesai and Simon X Benito.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., ARK Investment Management LLC and Keybank National Association OH. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Angel Cabrera, Morton Collins, Niranjan Sardesai and Simon X Benito.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Inovio Pharmaceuticals stock cost?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $6.60.

Inovio Pharmaceuticals (NASDAQ:INO) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Earnings History Chart

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Dividend History Chart

Dividend Payments by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Last Updated on 2/22/2017 by MarketBeat.com Staff